Amneal reported third-quarter 2026 net revenue of $863 million, up 10%, and Adjusted EBITDA of $207 million, up 30%, but swung to a GAAP net loss of $22 million from net income a year earlier, driven by acquisition and integration costs and a higher tax provision. The company raised its full-year 2026 revenue, Adjusted EBITDA and adjusted EPS guidance, while lowering its operating cash flow guidance, which it attributed to higher inventory levels.
Q3 2026 net revenue was $863 million, up from $785 million in Q3 2025; Adjusted EBITDA was $207 million, up 30%.
GAAP net loss attributable to Amneal was $22 million, or $(0.06) per diluted share, compared with net income of $2 million a year earlier; adjusted diluted EPS was $0.26, up 53% from $0.17.
Full-year 2026 net revenue guidance rose to $3.15 billion to $3.25 billion from $3.10 billion to $3.20 billion; Adjusted EBITDA guidance rose to $800 million to $815 million from $750 million to $780 million.
Operating cash flow guidance was lowered to $325 million to $375 million from $350 million to $400 million, reflecting working capital, including higher inventory levels.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Amneal Pharmaceuticals's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$3.02B
+8.0%
$0.22
—
2.4%
FY2024
$2.79B
+16.7%
$-0.38
—
-4.2%
FY2023
$2.39B
+8.2%
$-0.48
—
-3.5%
FY2022
$2.21B
+5.7%
$-0.86
-1328.6%
-12.2%
FY2021
$2.09B
+5.1%
$0.07
-88.5%
0.6%
Frequently asked questions
When is Amneal Pharmaceuticals's next earnings date?
Amneal Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Amneal Pharmaceuticals earn last quarter?
For the quarter ended Jun 2026, Amneal Pharmaceuticals reported diluted EPS of $0.18 (+157.1% year over year) on revenue of $796.20M (+9.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.